Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2011

View Archived Issues

Preclinical and clinical phase I/II data presented on GSK-573719 for COPD

Novel SMYD2 inhibitor identified at AstraZeneca

Novel pan-Aurora kinase inhibitor is active against drug-resistant cancer cells

Novel CO-releasing rhenium complexes developed at Swiss university

Phosphagenics to advance development of twice-weekly oxycodone patch

Enrollment complete in pediatric Xerecept trial

Incozen Therapeutics describes new PI3K-delta inhibitor

Creabilis raises funds for development of CT-327

Scientists at GSK prepare new lysophospholipid S1P1 receptor agonists

Novel neuroprotective agents patented

New saRNA molecules claimed by University of California scientists

Novel PP1 inhibitors synthesized

EntreMed reports encouraging phase II results on ENMD-2076

Fibrocell Science launches laViv in U.S.

InSite Vision releases phase II pharmacokinetic data on BromSite

Intellect Neurosciences and ViroPharma enter licensing agreement for OX-1

CalciMedica presents novel protein orai-1 inhibitors

NuPathe reports encouraging data from migraine patch trial

Gliknik receives SBIR contract to advance stradobodies

Merck Serono and Ono Pharmaceutical collaborate on MS drug and cancer vaccine

G-Zero Therapeutics receives NIH grant for studies in radiation exposure

Karo Bio enrolls first patient in AKKA study

Neurocrine and Abbott reach second milestone in elagolix collaboration

First patients dosed with Xiaflex in Dupuytren's contracture multicord study

Cariprazine study meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...